Skip to content

Effect of Liposomal Bupivacaine versus Ropivacaine in Adductor Canal Block on Pain and Early Function after Total Knee Arthroplasty

Effect of Liposomal Bupivacaine versus Ropivacaine in Adductor Canal Block on Pain and Early Function after Total Knee Arthroplasty

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093350
Enrollment
Unknown
Registered
2024-12-03
Start date
2023-10-16
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain after Total Knee Arthroplasty

Interventions

Experimental Group:Postoperative adductor canal block with 133mg(20ml) liposomal bupivacaine at affected limb
Control group:Postoperative adductor canal block with 80mg(20ml) ropivacaine at affected limb

Sponsors

Guangdong Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients planning to undergo unilateral total knee arthroplasty. 2.Age >= 18 years old.

Exclusion criteria

Exclusion criteria: 1. Patients with neurological or mental diseases that may affect pain or cognitive function (such as Alzheimer's disease, schizophrenia, depression, trigeminal neuralgia, painful diabetes peripheral neuropathy, post herpetic neuralgia, etc.); 2. Patients with severe systemic diseases (such as heart failure, myocardial infarction, cerebrovascular infarction, chronic kidney disease, severe connective tissue disease, active peptic ulcer disease, malignant tumors, etc.); 3. Patients who regularly use glucocorticoids or opioid drugs (such as morphine, fentanyl, hydromorphone, ketobemide, methadone, nicomorphine, oxycodone, or pethidine, etc.); 4. Patients who are allergic to local anesthetic drugs such as bupivacaine and ropivacaine; 5. The ipsilateral knee joint has undergone surgery (such as total knee arthroplasty, knee single condyle arthroplasty, arthroscopic surgery, fracture open reduction and internal fixation surgery, etc.) or has undergone surgery on other parts within the past 3 months; 6. Patients diagnosed with rheumatoid arthritis; 7. Patients with Glycated Hemoglobin (HbA1c)>8%; 8. Patients with severe osteoporosis; 9. The researchers believe that patients are unlikely to comply with the trial requirements after randomization; 10. The patient is receiving the investigational drug as part of another clinical trial.

Design outcomes

Primary

MeasureTime frame
Visual analogue scale (VAS) score after surgery;

Secondary

MeasureTime frame
Quadriceps muscle strength;Knee joint range of motion;Knee joint function score;Postoperative morphine consumption;Perioperative adverse reactions (nausea, vomiting, fever, pruritus, constipation);

Countries

China

Contacts

Public ContactDeng Zhantao

Guangdong Provincial People's Hospital

dengzhantao@gdph.org.cn+86 187 5185 1015

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026